Background: Treatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B analog microtubule inhibitor, in patients with metastatic CRPC with or without previous taxane exposure. Results: In total, 108 patients were assessable for safety (50 were taxane-pretreated) and 105 for efficacy in the perprotocol population. The median age of patients was 71 years and median number of cycles was 4. PSA decreases of ‡50% were achieved in 22.4% and 8.5% of taxane-naive and taxane-pretreated patients, respectively. The most common grade 3/4 adverse event was neutropenia, seen in 22.4% of chemo-naive and 40% of taxane-pretreated men. Grade 3 peripheral neuropathy occurred in none of the taxane-naive patients and 6.0% of taxane-pretreated patients.
introduction
Patients with progressive metastatic castration-resistant prostate cancer (CRPC) demonstrate suboptimal outcomes. Randomized trials have established the modest benefit of frontline docetaxel-based chemotherapy for metastatic CRPC, yielding a median survival of 19 months [1, 2] . The inevitability of disease progression underscores the continuing need for novel therapies.
Resistance to docetaxel has been associated with altered expression of b-tubulin isotypes, e.g. b-tubulin III [3] . Eribulin mesylate (E7389) is a structurally simplified, synthetic analog of the marine sponge-derived natural product, halichondrin B, which may overcome such resistance. Eribulin inhibits microtubule dynamics by suppressing microtubule polymerization and sequesters tubulin into nonfunctional aggregates [4] . Eribulin has demonstrated preclinical activity against prostate cancer as well as cancer cells that are paclitaxelresistant due to b-tubulin mutations [5, 6] . Phase I clinical trials have established the safety of eribulin for solid tumors [7, 8] . We therefore conducted a nonrandomized phase II clinical trial (NCT00278993) to evaluate the efficacy and safety of eribulin in patients with metastatic CRPC with or without prior exposure to taxane therapy.
patients and methods

study design
This multicenter, open-label, two-stage design, single-arm phase II study evaluated eribulin in patients with metastatic CRPC in two separate strata: those with and those without prior taxane exposure ( Figure 1 ). The trial was approved by local regulatory authorities and institutional review boards and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before study entry. The primary efficacy end point was prostate-specific antigen (PSA) response [9] . Secondary end points included duration of PSA response, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Pharmacogenomic analysis of available tumor tissue was used to explore the relationship between certain tubulin isoforms or microtubule-associated proteins and sensitivity to eribulin.
patients
Patients were required to have histologically proven prostate cancer with metastatic disease and an Eastern Cooperative Oncology Group (ECOG) performance status of zero to two. Documented PSA progression, defined as a minimum of three serum PSA values taken ‡1 week apart to document two consecutive rises in PSA with the last value being ‡5 ng/ml, was required (with or without radiographic or symptomatic progression), despite maintenance of castrate-level testosterone with orchiectomy or luteinizing hormone-releasing hormone analog and appropriate antiandrogen withdrawal. Adequate bone marrow [absolute neutrophil count (ANC) ‡1.5 · 10 9 /l, hemoglobin ‡9.0 g/dl (or 5.5 mmol/l), and platelet count ‡100 · 10 9 /l], liver [bilirubin £1.5 · upper limit of normal (ULN), alanine transaminase, and aspartate transaminase £3 · ULN (in the case of liver metastases £5 · ULN)], and renal function (serum creatinine £1.5 · ULN or calculated creatinine clearance ‡40 ml/min per the Cockcroft and Gault formula) were required. Patients were required to have received no prior chemotherapy (except mitoxantrone or estramustine) in the taxane-naive cohort or must have failed no more than one previous chemotherapeutic regimen with a taxane in the taxane-pretreated cohort. Key exclusion criteria included any cancer therapy £4 weeks of starting eribulin, radiation therapy encompassing ‡30% of bone marrow, prior radiopharmaceuticals, need for warfarin or related compounds (low-dose warfarin was allowed), severe/uncontrolled intercurrent illness, significant cardiovascular impairment, preexisting neuropathy grade >2, and central nervous system metastasis.
treatment
Eribulin mesylate (1.4 mg/m 2 ) was administered as a 2-to 5-min i.v.
bolus infusion on days 1 and 8 of a 21-day cycle. The dose was reduced to 1.1 mg/m 2 on day 1 of a subsequent cycle if one of the following occurred during the previous cycle: grade 4 neutropenia for >7 days, grade 3 or 4 neutropenia with fever or infection, grade 4 thrombocytopenia or ‡grade 3 thrombocytopenia requiring platelet transfusion, any grade 3 or 4 nonhematological toxicity that returned to grade £2 within 7 days, and delay of treatment by >7 days due to persisting toxicity. Treatment on day 8 was delayed in the event of hematological (ANC <1.0 · 10 9 /l and/or platelet count <75 · 10 9 /l) or nonhematological toxic effects (any grade >2, except inadequately treated nausea and/or vomiting). If recovery occurred before day 15, treatment resumed and the next treatment day was considered the new day 8, with a reduced dose. If recovery did not occur before day 15, the day-8 dose was omitted and treatment was resumed on day 1 of the next cycle. A second-dose reduction was permitted to 0.7 mg/m 2 for grade 3/4 nonhematological toxicity in patients benefiting from treatment.
Patients continued on eribulin until unacceptable toxicity, disease progression as determined by Bubley criteria or RECIST, investigator decision, or patient withdrawal of consent (no maximum number of cycles was stipulated) [9, 10] . If, in the setting of improving PSA levels and stable or improving visual analog scale (VAS) scores, a new lesion was discovered on a bone scan that could be nonmalignant, then the study treatment could be continued at the discretion of the investigator.
Concomitant use of antiemetics, antidiarrheal therapy, antiallergic medication (corticosteroids and antihistamines), granulocyte colonystimulating factor, granulocyte-macrophage colony-stimulating factor, and erythropoietin was allowed. Palliative radiotherapy on £10% of the bone marrow was permitted during the study. Potent inhibitors or inducers of CYP3A4 were not allowed. efficacy and safety assessments PSA was measured before each cycle. Tumor assessments consisting of objective radiological evaluation of the chest, abdomen, and pelvis were carried out at baseline and every two cycles or sooner if clinically warranted. Bone scan was carried out at baseline and after every three cycles. Pain was estimated by VAS scores every cycle. PSA response was defined as a ‡50% decrease in the PSA level that was confirmed by another measurement at least 4 weeks later (by Prostate-Specific Antigen Working Group criteria) [9] . Duration of PSA response was defined as the time from the first 50% PSA decrease to confirmed PSA progression. Radiological response was assessed as per RECIST 1.0 criteria [10] .
Safety evaluations to identify adverse events (AEs) included physical examination, vital signs, electrocardiogram assessments, and clinical laboratory tests carried out at each visit. AEs were graded using the National Cancer Institute-Common Terminology Criteria version 3.0.
statistical analysis
The per-protocol (PP) population was the primary analysis set for efficacy in this study and included patients who fulfilled key eligibility criteria, had no major protocol violations, and completed one or more cycle. The intentto-treat population included all patients who received one or more dose of eribulin and was the primary analysis set for safety.
The primary efficacy analysis calculated PSA response rate. Sample size estimates were based on Simon's optimal two-stage design [11] . For taxane-
original articles Annals of Oncology naive patients, P 0 was set at 13% and P 1 at 30% (a PSA response of 45% is reported with docetaxel and prednisone; however, given that PSA declines are observed with prednisone alone, our expected response rate was adjusted to account for the use of eribulin as a single agent). With a 5% probability of a type I error and a 10% chance of a type II error (power 90%) at the specified P 0 and P 1 , if four or more responses were seen in 22 patients at stage I, a total of 57 patients were to be recruited. If 12 or more out of 57 patients demonstrated a PSA response, eribulin was to be considered active and the null hypothesis was to be rejected.
For taxane-pretreated patients, P 0 was set at 5% and P 1 at 20%; if two or more PSA responses were observed among 21 patients during the first stage, a total of 41 patients were to be recruited. If five or more responses were observed among 41 patients completing the second stage, the treatment was to be considered active and the null hypothesis was rejected. Demographics and baseline characteristics were summarized using descriptive statistics. Kaplan-Meier estimates were calculated and plotted for time-to-event end points including PFS and OS. Table 1 . Bone (80.6%) and lymph nodes (50.0%) were the most frequently involved metastatic sites and visceral metastases were present in 40.7% of patients (Table 1) . Most patients (48.1%) had only one lesion site at baseline and 11.1% had between two and four sites (Table 1) .
study drug exposure
The median number of treatment cycles received per patient in the taxane-naive group was 4.0 (range 1-47 cycles) and in the taxane-pretreated group was 3.0 (range 1-16 cycles). Of the 108 patients treated, 10 (9.3%) experienced a dose interruption, delay, or reduction in cycle 1. Overall, dose delays/interruptions and reductions due to an AE were needed for 23.1% and 13.9% of patients, respectively. Discontinuations due to progressive disease accounted for 35/58 (60.3%) in the taxane-naive group and 30/50 (60.0%) in the taxane-pretreated group. Discontinuations due to AEs accounted for 13/58 (22.4%) in the taxane-naive group and 11/50 (22.0%) in the taxanepretreated group.
PSA response and duration of response
Both study groups (taxane-naive and taxane-pretreated) met the criteria for continuation into the second stage. The PSA response rate was 22.4% [95% confidence interval (CI) 12.5-35.3] for taxane-naive patients versus 8.5% (95% CI 2.4-20.4) for taxane-pretreated patients. Given that ‡30% PSA declines have been described as a better indicator of OS, we also examined this parameter [12, 13] . PSA declines of ‡30% Table 2) . Based on PSA progression, bone scan progression, or progressive measurable disease by RECIST, 27.6% of taxanenaive patients experienced disease progression as their best overall response versus 31.9% in taxane-pretreated patients (Table 3) . Median duration of PSA response was 3.2 months (range 1.0-30.6 + , with ' + ' = censored observation) for taxanenaive patients ( Figure 3A) . Median duration of response could not be calculated for taxane-pretreated patients (range 1.2
+ months) as three of four responders were censored.
RECIST-defined tumor response
Thirty-three (56.9%) and 29 (61.7%) patients in the taxanenaive and taxane-pretreated groups, respectively ( (Figure 4 ). There were no partial responses observed in taxane-pretreated patients, but 69% had SD of ‡12 weeks. Figure 3C ).
symptom improvement
Among PSA responders, an improvement in ECOG performance score was demonstrated in 33.3% of patients in the chemo-naive group and none in the taxane-pretreated group. An improvement in the VAS pain score was seen in all responding patients in both groups and analgesic consumption decreased in 16.7% of chemo-naive patients and none in the taxane-pretreated group. Among PSA nonresponders, an improvement in ECOG performance score was seen in 24.0% of the chemo-naive group and 11.8% of the pretreated group, while an improvement in VAS pain score was seen in 88.0% of the chemo-naive group and 79.4% of the taxane-pretreated group. Analgesic consumption decreased in 16.0% of patients in the chemo-naive group and 11.8% in the pretreated group. (A) Kaplan-Meier estimates of duration of response (per-protocol population; no prior taxane therapy n = 13, 7 patients censored; prior taxane therapy n = 4, 3 patients censored); (B) Kaplan-Meier estimates of progression-free survival (per-protocol population; no prior taxane therapy n = 58, 15 patients censored; prior taxane therapy n = 47, 11 patients censored); (C) Kaplan-Meier estimates of overall survival (per-protocol population; no prior taxane therapy n = 58, 44 patients censored; prior taxane therapy n = 47, 28 patients censored).
original articles Annals of Oncology (above the median) of either TUBB2C or STMN1 with prolonged PFS (P = 0.024 and 0.007, respectively) but not with PSA response or OS. Expression levels of the other four genes analyzed (TUBB3, TUBB6, MAPT, and MAP4) did not show a significant association with any of these outcomes.
discussion
This nonrandomized phase II study demonstrated that eribulin mesylate can be safely administered and has antitumor activity in taxane-naive and taxane-pretreated patients with metastatic CRPC. Post-treatment declines in PSA of ‡50% were achieved in 22.4% and 8.5% of taxane-naive and taxane-pretreated patients, respectively, while declines of ‡30% occurred in 32.8% and 19.1% of taxane-naive and taxane-pretreated patients, respectively. The accrued patient population was typical for trials of metastatic CRPC, with predominantly bone metastases (in 80.6%) and visceral disease (in 40.7%). An objective response (RECIST) was observed in 15.2% of patients with measurable disease in the taxane-naive group, while no objective responses were seen in taxane-pretreated patients. While the median PFS was short for both groups (2.1 and 1.9 months, respectively), the median OS rates were 20.8 and 15.1 months, respectively, supporting further evaluation of eribulin in this patient population. These data are consistent with the results of another phase II trial conducted by ECOG that demonstrated activity for eribulin [15] . Preliminary pilot studies revealed a significant association of high tumor expression levels of TUBB2C or STMN1 with prolonged PFS, which merits further evaluation. It is noteworthy that in our trial eribulin was not combined with prednisone, as in the pivotal trials that evaluated docetaxel and prednisone and yielded a PSA response rate of 45% [1, 2] . Prednisone alone may induce ‡50% PSA declines in up to 22% of patients [16] .
Eribulin was administered as a rapid i.v. bolus and without steroid premedication; the latter may be an advantage in a population with comorbidities, e.g. diabetes mellitus. In addition, the compound demonstrated a manageable toxicity profile consistent with other phase II studies [17] . The most common grade 3/4 AE associated with eribulin treatment was neutropenia observed in 30.5% of all patients, although febrile neutropenia was seen in only 3.7%. Peripheral neuropathy was reported in only 13.9% of all patients, of whom, only 2.8% had grade 3 neuropathy; none had grade 4 neuropathy. Eribulin was not highly emetogenic (routine antiemesis prophylaxis was not required) and fatigue and diarrhea were generally mild and manageable. While these toxic effects appear similar to those of docetaxel, nail changes and peripheral edema were infrequent or absent. Despite a generally favorable toxicity profile, discontinuations due to toxic effects occurred in 22% of patients in both strata. While the reasons for this finding are unclear, the numbers of patients discontinued per strata are small [10] [11] [12] and concurrent corticosteroids might have alleviated some toxic effects and symptoms and enhanced the possibility of a longer course of chemotherapy.
One of the limitations of our trial is that it was designed and accrual was completed before new CRPC trial design recommendations were issued, and the older Bubley and conventional RECIST criteria were employed to determine progression [9, 10, 14] . The most recent guidelines by the PCWG-2 recommend a minimum of 12 weeks of therapy before radiological evaluation and the reporting of ‡50% and ‡30% PSA declines as opposed to PSA responses. In our trial, computed tomography scans were carried out every two cycles (6 weeks) and bone scans were carried out every three cycles (9 weeks), which may have led to early discontinuation in some patients due to PSA surges or bone scan flare responses, which is suggested by the median number of cycles being only three to four. Indeed, a large proportion (40%) progressed by PSA criteria alone leading to removal from therapy. PSA response rates in the PCWG-2 clinical subtypes appeared similar to the overall PSA response rates in the taxane-naive and taxane-pretreated groups, although few patients constituted the node-only subtype (Table 2) . Potentially, the activity of eribulin may have been higher with the implementation of these new guidelines.
Despite this, the activity of eribulin observed in our trial needs to be interpreted in the context of emerging agents for the therapy of metastatic CRPC. Cabazitaxel extended median survival in the second-line setting (15.1 versus 12.7 months) when compared with mitoxantrone and was recently approved [18] . This median survival of 15 months with cabazitaxel is similar to that seen in our second-line taxane-pretreated group. Sipuleucel-T, an autologous dendritic cell vaccine pulsed with prostatic acid phosphatase-granulocyte/macrophage-colony stimulating factor, extended survival in relatively asymptomatic men and was also approved [19, 20] . Promising androgen pathway targeting agents like abiraterone acetate and MDV3100 have demonstrated substantial activity in CRPC in phase III trials [21, 22] . Indeed, abiraterone acetate was recently reported to significantly extend survival in men with progressive metastatic CRPC following prior docetaxel treatment, leading to regulatory approval [23] . In addition to eribulin, other tubulin-targeting agents have demonstrated activity in metastatic CRPC, e.g. the epothilones. Patupilone is being compared with docetaxel in a randomized phase II trial for metastatic CRPC based on activity in a phase II trial [24] . Ixabepilone has demonstrated antitumor activity similar to that of docetaxel [25, 26] and displayed promising activity when combined with mitoxantrone in the second-line setting [27] . Overall, the results of these ongoing trials will be important in determining the role of eribulin in the treatment of CRPC. It is also noteworthy and encouraging that eribulin has been shown to extend OS in heavily pretreated women with metastatic breast cancer (MBC) in a pivotal phase III trial when compared with physicians' treatment choice [28] . Based on the results of this study, eribulin mesylate has recently gained approval in the United States for patients with MBC who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
To conclude, eribulin mesylate demonstrated moderate antitumor activity and a favorable toxicity profile in patients with chemo-naive or taxane-pretreated metastatic CRPC. The further development of eribulin in both the frontline and the salvage settings for patients with CRPC may be warranted in comparison with currently employed agents (docetaxel, cabazitaxel) with a particular focus on toxic effects, or as thirdline salvage chemotherapy where a tolerable agent may play a palliative role. Alternatively, eribulin may be specifically developed in CRPC patients with poorer performance status or comorbidities to capitalize on its favorable toxicity profile and lack of need for concurrent corticosteroids. A focus on developing molecular predictors of benefit may further define eribulin's role in the emerging therapeutic armamentarium for CRPC. 
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